Gary Stetz Sells 87,851 Shares of Hillstream Biopharma (NASDAQ:CNTN) Stock

Posted by Latisha Jones on May 29th, 2026

Hillstream Biopharma Inc. (NASDAQ:CNTN – Get Free Report) Director Gary Stetz sold 87,851 shares of the company’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $3.42, for a total transaction of $300,450.42. Following the sale, the director directly owned 146,675 shares of the company’s stock, valued at $501,628.50. This represents a 37.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Hillstream Biopharma Stock Down 3.7%

CNTN stock opened at $3.11 on Friday. Hillstream Biopharma Inc. has a one year low of $1.08 and a one year high of $9.08. The stock has a market capitalization of $217.11 million, a price-to-earnings ratio of -2.70 and a beta of 1.44. The firm’s 50-day moving average price is $3.31.

Hillstream Biopharma (NASDAQ:CNTN – Get Free Report) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.23) EPS for the quarter.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Wall Street Zen raised shares of Hillstream Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings lowered shares of Hillstream Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 15th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Read Our Latest Stock Analysis on CNTN

About Hillstream Biopharma

(Get Free Report)

Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.